Quantcast

Latest Preotact Stories

2011-02-23 01:46:39

Preliminary research indicates that use of nitroglycerin ointment among postmenopausal women for 2 years was associated with a modest increase in bone mineral density and decrease in bone resorption (loss), according to a study in the February 23 issue of JAMA. "The number of osteoporotic fractures is increasing worldwide as populations age. An inexpensive and widely available treatment may help limit this increase," the authors write. "Nitroglycerin stimulates bone formation and inhibits...

2011-01-25 11:55:24

Recommendations provide diagnosis, treatment guidance for postmenopausal women The American Association of Clinical Endocrinologists (AACE) has released new medical guidelines for the diagnosis and treatment of postmenopausal osteoporosis. Loyola physician Pauline Camacho, MD, was part of a committee that developed the guidelines to manage this major public health issue. These recommendations were developed to reduce the risk of osteoporosis-related fractures and improve the quality of life...

2010-12-13 14:21:03

New Delhi researchers show that vitamin D levels may be a useful index for the assessment of hip fracture risk in elderly people. A study in New Delhi India has revealed high rates of vitamin D deficiency among hip fracture patients, confirming the conclusions of similar international studies which point to vitamin D deficiency as a risk factor for hip fracture. A group of 90 hip fracture patients was compared to a matched control group of similar age, sex and co-morbidity. Of the patients...

2009-12-18 06:06:00

THOUSAND OAKS, Calif., Dec. 18 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has announced a positive opinion for the marketing authorization of Prolia((TM)) (denosumab) for the treatment of osteoporosis in postmenopausal women at increased risk of fractures, and for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased...

2009-08-11 09:05:00

THOUSAND OAKS, Calif., Aug. 11 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN) today announced the publication of results from two pivotal Phase 3 studies investigating the safety and effectiveness of denosumab at reducing fracture risk in more than 7,800 women with postmenopausal osteoporosis and in more than 1,400 men with non-metastatic prostate cancer undergoing androgen deprivation therapy (ADT) leading to bone loss. In both studies, published today in The New England Journal of...

2009-08-05 07:30:00

CAMBRIDGE, Mass., Aug. 5 /PRNewswire/ -- Radius Health ("Radius") today announced topline Phase 2 data demonstrating that in women with osteoporosis, BA058 -- the company's novel PTHrP (parathyroid hormone-related protein) analog -- significantly increased bone mineral density (BMD) at the lumbar spine and femoral neck (a common fracture site located in the hip joint) after six months of therapy. The gains in lumbar spine and femoral neck BMD were further increased in a subset of patients...

2009-02-19 14:55:00

COLLEGEVILLE, Pa., Feb. 19 /PRNewswire-FirstCall/ -- The Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), today adopted a positive opinion recommending to grant a marketing authorization for CONBRIZA(TM) (bazedoxifene) for the treatment of postmenopausal osteoporosis in women at increased risk of fracture. CONBRIZA, an investigational medicine, is in development by Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE)....

2009-01-06 10:32:00

BEDFORD, Mass., Jan. 6 /PRNewswire/ -- MicroCHIPS, Inc., a developer of intelligent implanted devices, has named Massachusetts General Hospital endocrinologist, Robert M. Neer, MD, to its Scientific Advisory Board. MicroCHIPS' has partnered with prominent clinicians to form a Scientific Advisory Board to support the company's innovative biosensing and drug delivery programs in diabetes, osteoporosis and other chronic diseases. As a leading physician and researcher in osteoporosis, Dr. Neer...

2008-10-27 12:00:29

Zosano Pharma, Inc., a privately held pharmaceutical company developing a novel transdermal delivery technology, today announced positive results from its phase 2, randomized, multi-center, double-blind, multi-dose study designed to determine safety and efficacy of its ZP-PTH rapid delivery patch for the treatment of osteoporosis. The product delivers PTH 1-34, teriparatide (PTH), a compound that has been proven to stimulate formation of new bone and reduce the risk of fractures. The ZP-PTH...

2008-10-26 09:00:06

Cytochroma has initiated a Phase II clinical trial of CTA018 injection, the company's product candidate for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease. The Phase II clinical trial is an open-label, dose-escalating pharmacokinetic, pharmacodynamic, efficacy and safety study of CTA018 injection in chronic kidney disease (CKD) patients with secondary hyperparathyroidism (SHPT) undergoing hemodialysis. The Phase II study is being conducted in Canada...


Word of the Day
tessitura
  • The prevailing range of a vocal or instrumental part, within which most of the tones lie.
This word is Italian in origin and comes from the Latin 'textura,' web, structure.